Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Mirapex

Mirapex
In stock
0.125mg · 0.25mg · 0.5mg
from 31,34 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
37,61 £31,34 £
1,04 £ per tablet

In brief

  • In our pharmacy you can buy Mirapex without a prescription, with delivery in 9–21 days throughout the United Kingdom and discreet, anonymous packaging; please note that pramipexole is a prescription‑only medicine in the UK and is normally used under medical supervision.
  • Mirapex (pramipexole) is used for Parkinson’s disease and restless legs syndrome; it is a dopamine agonist that stimulates dopamine D2/D3 receptors to improve motor symptoms and reduce the urge to move.
  • Usual dosage: Parkinson’s — immediate‑release typically starts at 0.125 mg three times daily, increasing by 0.125 mg TID every 5–7 days up to a maximum of 4.5 mg/day (ER start 0.375 mg once daily, titrate up to 4.5 mg/day); restless legs syndrome — 0.125 mg once daily 2–3 hours before bedtime, titrated up to a maximum of 0.75 mg once daily.
  • Form of administration: oral tablets (immediate‑release and extended‑release formulations).
  • Onset time: immediate‑release usually begins to take effect within about 30–60 minutes; extended‑release formulations take longer to reach full effect.
  • Duration of action: immediate‑release effects typically last around 8–12 hours; extended‑release formulations provide once‑daily coverage (approximately 24 hours).
  • Alcohol warning: avoid alcohol while taking Mirapex as it can increase drowsiness, dizziness and the risk of orthostatic hypotension and impair coordination.
  • The most common side effect is nausea; other frequent effects include drowsiness, fatigue, insomnia, dizziness, hallucinations, constipation and peripheral oedema.
  • Would you like to try Mirapex without a prescription?

Basic Mirapex information

  • INN (international nonproprietary name): Pramipexole
  • Brand names available in the United Kingdom: Mirapexin; generic pramipexole tablets
  • ATC code: N04BC05
  • Forms and dosages: Immediate‑release tablets 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg and 1.1 mg (pramipexole base; equivalent to 0.125, 0.25, 0.5, 1 and 1.5 mg salt); prolonged‑release (ER) tablets 0.26 mg to 3.15 mg base (0.375 mg to 4.5 mg salt)
  • Manufacturers in the United Kingdom: Boehringer Ingelheim (innovator), generics from Teva, Accord Healthcare, Sandoz, Stada, Zentiva, Mylan, Krka
  • Registration status in the United Kingdom: Licensed (immediate‑ and prolonged‑release tablets); prescription-only medicine
  • OTC / Rx classification: Prescription-only medicine (POM)

Critical warnings, restrictions and patient protection (UK focus)

Your prescriber will prioritise safety when starting pramipexole for Parkinson’s disease or restless legs syndrome.

Pramipexole is prescription-only in the UK and should only be started and titrated under clinician supervision.

Elderly patients need tailored dosing because increased sensitivity and common renal impairment make slower titration safer.

Pregnancy and breastfeeding are generally discouraged while taking pramipexole unless the clinician judges benefits to outweigh risks.

Patients with severe renal impairment need dose adjustment or may need to avoid pramipexole entirely.

Relative contraindications include active psychotic disorders, a history of compulsive behaviours such as gambling or hypersexuality, and clinically important orthostatic hypotension.

Immediate red flags that require stopping the drug and seeking help include hallucinations, severe dizziness or fainting, sudden onset of daytime sleep attacks, and new compulsive behaviours.

  • Immediate red flags: Hallucinations, severe dizziness, fainting, sudden sleep episodes, new compulsive behaviour (eg gambling, hypersexuality)

Emergency action checklist for patients.

  • Stop taking pramipexole if you experience a red-flag symptom.
  • Contact your GP or NHS 111 for urgent advice if symptoms are moderate.
  • Go to A&E if you are fainting, severely drowsy, confused, or having dangerous behaviour.

Keep a printed checklist by your medication as a quick reference for carers and family.

Q&A — “Can I drive after taking it in the UK?”

Driving may be unsafe if pramipexole causes drowsiness, sudden sleep episodes or impaired concentration.

If you notice sleepiness or sudden sleep attacks, stop driving immediately and tell your prescriber.

  • Stop driving when affected by drowsiness or sudden sleep episodes and avoid hazardous tasks.
  • Notify the DVLA and your insurer if treatment affects your ability to drive, and seek prescriber or pharmacist advice.

Usage basics — names, legal status and UK availability

INN, brand names available in the UK

The International Nonproprietary Name is pramipexole.

In the UK pramipexole is sold as Mirapexin, and generics are widely available.

Both immediate-release and extended-release formulations are on the market to suit different dosing needs.

Legal classification (POM, P, GSL)

Pramipexole is prescription-only (POM) across the UK and must be prescribed by an authorised clinician under MHRA frameworks or equivalent UK regulatory arrangements.

Quick definitions for readers and clinicians.

  • INN: International Nonproprietary Name, here pramipexole.
  • Brand: Trade names such as Mirapexin in the UK.
  • ATC code: N04BC05 (dopamine agonists).

NHS supply routes include GP prescriptions, hospital specialist clinics and private neurology clinics for those choosing private care.

Available UK strengths commonly include 0.088 mg, 0.18 mg and 0.7 mg immediate-release tablets and a range of ER strengths.

Typical manufacturers supplying the UK market include Boehringer Ingelheim as the innovator and generics by Teva, Accord and Sandoz.

Dosing guide — NHS standard regimens and practical titration

Standard regimens (Parkinson’s disease; RLS)

For Parkinson’s disease the usual immediate-release starting dose is 0.125 mg three times daily or an ER start of 0.375 mg once daily.

When using immediate-release tablets the dose is commonly increased by 0.125 mg three times daily every 5–7 days as tolerated up to a typical maximum of 4.5 mg per day.

For restless legs syndrome (RLS) treatment often starts at 0.125 mg once nightly, given two to three hours before bedtime, and may be titrated to a usual maximum of 0.75 mg daily with 4–7 day intervals between increases.

Titration should be slower in older people and in those with renal impairment.

Condition Initial dose Titration interval Typical max
Parkinson’s disease 0.125 mg TID (IR) or 0.375 mg once daily (ER) Increase by 0.125 mg TID every 5–7 days (IR) 4.5 mg/day
Restless legs syndrome (RLS) 0.125 mg once nightly Titrate at 4–7 day intervals 0.75 mg/day

Titration monitoring checklist for prescribers and patients includes blood pressure checks, monitoring for daytime sleepiness, watching for impulse-control disorders and assessment for hallucinations or confusion.

NHS prescription length norms and reviews usually require an early check within 4–8 weeks after initiation to assess tolerability and response.

Use a dosing calendar or printable checklist to record dose changes and side effects for review appointments.

Q&A — “What if I miss a dose?”

If you miss a dose, take it as soon as you remember unless it is near the time for the next dose.

Do not double the next dose to make up for a missed one.

  • For once-daily ER doses, skip the missed dose and resume the usual dosing the next day.
  • Contact your GP or pharmacist, or NHS 111, if unsure what to do.

Interaction chart — food, drink and common drug conflicts

Food and drinks (alcohol, caffeine, diet)

Pramipexole has no major food interactions that prevent taking it with meals.

Alcohol increases the risk of sedation and dizziness when combined with pramipexole and should be limited when starting or increasing the dose.

Caffeine does not cause a clinically relevant interaction with pramipexole but may worsen insomnia or sleep disturbance in susceptible people.

Substance Effect Practical advice
Alcohol Increased sedation and dizziness Limit alcohol while starting or titrating
Caffeine May worsen sleep disturbance Reduce late-day caffeine if insomnia occurs
Food No significant interaction Take with or without food as instructed

Common drug conflicts

Pramipexole interacts with other dopaminergic agents and drugs that affect the central nervous system.

Antipsychotics may antagonise the effects of pramipexole and worsen motor control in Parkinson’s patients.

CNS depressants produce additive sedation when combined with pramipexole and caution is needed with benzodiazepines, opioids and some antihistamines.

Antihypertensive medicines can increase the risk of orthostatic hypotension when used with pramipexole.

Patients should have a pharmacist review all medicines including OTC, herbal and recreational drugs to check for interactions.

Reporting suspected adverse interactions via the MHRA Yellow Card scheme is encouraged to support UK pharmacovigilance.

Legal status and availability in the UK

In our online pharmacy, Mirapex is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism of action and pharmacology (simple and clinical)

Simplified explanation

Pramipexole is a dopamine agonist that stimulates D2 and D3 receptors in the brain to compensate for dopaminergic deficiency in Parkinson’s disease.

It also modulates pathways implicated in restless legs syndrome to reduce uncomfortable sensations and the urge to move.

Pramipexole is classified under ATC code N04BC05 as a dopaminergic agent.

Clinical terms

Immediate-release tablets are taken multiple times per day while extended-release formulations allow once-daily dosing.

Pramipexole is predominantly excreted by the kidneys, so dose adjustments are required in renal impairment.

Indications and off-label uses (MHRA and NHS practice)

MHRA-approved uses

Approved indications include Parkinson’s disease and restless legs syndrome (RLS).

Pramipexole is often used as a first-line option in early Parkinson’s and as monotherapy for RLS.

Off-label practices in NHS and private care

Off-label use is uncommon and should be specialist-led with clear documentation and informed consent.

  • Reasons to consider alternatives include comorbid psychosis and severe renal failure.

Prescribers using off-label treatments should document the rationale, discuss risks with the patient and agree a follow-up plan.

Refer complex cases to specialist neurology clinics for personalised management plans.

Alternatives matrix — other dopamine agonists and choices

NHS prescribing alternatives (comparison table)

Drug Formulation Dosing convenience Typical side effects NHS availability
Ropinirole Oral tablets, IR/ER Once-daily ER available Sleepiness, nausea, impulse behaviours Widely available as generic
Rotigotine Transdermal patch Once-daily patch Skin irritation, nausea, drowsiness Available, useful if GI issues present
Apomorphine Injection/infusion Rescue therapy or continuous infusion Injection-site reactions, nausea Specialist use in advanced disease
Bromocriptine Oral tablets Multiple daily dosing GI upset, hypotension Less commonly used now

Pros and cons checklist

Match the treatment to the patient’s lifestyle and comorbidities when choosing between oral pramipexole, ropinirole or a rotigotine patch.

Consider patch therapy such as rotigotine if adherence or gastrointestinal absorption are concerns.

Discuss the risk of impulse-control disorders with all dopamine agonists and individualise choice based on renal function and patient preference.

Recommended shared decision-making points include dosing frequency, side-effect profile and monitoring plan.

Common questions from UK patient consultations

How long until it works?

Motor effects in Parkinson’s can be noticed within days to weeks, while RLS benefit may occur within days.

What side effects should I expect?

Common effects include nausea, sleepiness, dizziness, constipation and occasional hallucinations.

Will it interact with my current meds?

Check with a pharmacist for interactions, especially with antipsychotics, CNS depressants and antihypertensives.

  • Red-flag symptoms requiring urgent contact: sudden sleep attacks, severe hallucinations, fainting, new compulsive behaviours.

Keep a symptoms diary and attend scheduled reviews to allow dose adjustment and safety monitoring.

Registration and regulation (MHRA and prescribing framework)

MHRA approval process

Pramipexole formulations such as Mirapexin are authorised in the UK by the MHRA.

Prescribers should remain within licensed indications and document any off-label use with a clear rationale.

NHS prescribing framework

Responsibility for initiating treatment typically rests with GPs or specialists, with shared care agreements used for long-term management.

Monitoring obligations include blood pressure, renal function checks and mental health assessments to look for hallucinations or impulse-control disorders.

Report suspected adverse drug reactions through the Yellow Card scheme to help UK safety monitoring.

Storage, handling and disposal (UK household context)

UK household storage (cold/damp climate)

Store pramipexole at room temperature between 15–30°C and keep it away from moisture and direct light.

Keep tablets in their original blister pack and avoid storing medicines in bathrooms where dampness is common.

Always keep medicines out of reach of children and pets.

Guidance from NHS and pharmacists

Do not use tablets past their expiry date and do not split extended-release tablets.

When travelling keep a copy of your prescription and carry medicines in original packaging for customs checks if required.

For disposal return unwanted medicines to a pharmacy take-back service or follow local council household waste guidance as advised by the NHS.

Guidelines for proper use — pharmacist counselling and NHS patient safety advice

UK pharmacist counselling style

Pharmacists should confirm the indication and the exact dose and titration plan with the patient at the point of dispensing.

Key counselling points include common side effects, how to manage nausea, the risk of drowsiness, driving and work safety advice, and guidance on impulse-control risks.

Advise patients to limit alcohol and to report any unusual behaviours promptly.

Arrange follow-up and remind patients of the review window within 4–8 weeks after starting treatment.

NHS patient safety advice

Patients are advised to keep an up-to-date medicines list and to report adverse drug reactions via the Yellow Card scheme or to their GP.

Attend review appointments and keep a diary of symptoms and side effects to support clinical decisions.

Consider printed patient information leaflets summarising dose instructions, side effects and when to seek urgent care.

Delivery across the United Kingdom

City Region Delivery Time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Glasgow Scotland 9–21 days
Leeds West Yorkshire 9–21 days
Liverpool Merseyside 9–21 days
Edinburgh Scotland 9–21 days
Cardiff Wales 9–21 days
Bristol South West 9–21 days
Belfast Northern Ireland 9–21 days
Newcastle Tyne and Wear 9–21 days
Southampton South East 9–21 days
Plymouth Devon 9–21 days

Closing notes for patients and clinicians

Pramipexole, sold as Mirapexin among others, is an effective dopamine agonist used for Parkinson’s disease and RLS when prescribed and monitored correctly.

Start at low doses and titrate carefully, especially in older patients and those with renal impairment.

Monitor for sleepiness, orthostatic hypotension, hallucinations and new impulsive behaviours throughout treatment.

Use trusted NHS sources and specialist clinics for complex decisions and always consult a pharmacist or GP about interactions with current medicines.

For further help with medicines, speak to your local community pharmacist and keep all reviews within the NHS recommended timeline.

Related products